Celyad SA (CYAD) News
Filter CYAD News Items
CYAD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CYAD News Highlights
- CYAD's 30 day story count now stands at 3.
- Over the past 10 days, the trend for CYAD's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CYAD are CELL and PR.
Latest CYAD News From Around the Web
Below are the latest news stories about CELYAD ONCOLOGY SA that investors may wish to consider to help them evaluate CYAD as an investment opportunity.
Celyad Oncology Announces Receipt of Nasdaq Delisting NoticeMONT-SAINT-GUIBERT, Belgium, May 15, 2023--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. |
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From NasdaqMONT-SAINT-GUIBERT, Belgium, May 05, 2023--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that its Board of Directors has approved the voluntary delisting of its American Depositary Shares representing ordinary shares ("ADSs") from the Nasdaq Global Market, termination of its American Depositary Receipt ("ADR") facility and deregistration w |
Celyad Oncology Reports First Quarter 2023 Financial Results and Recent Business HighlightsMONT-SAINT-GUIBERT, Belgium, May 05, 2023--PR Q1 results |
Celyad Oncology Announces Receipt of Nasdaq Initial Notification on ADS Bid PriceMONT-SAINT-GUIBERT, Belgium, April 24, 2023--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the "Bid Price Notice") on April 19th, 2023 from The Nasdaq Stock Market ("Nasdaq") informing the Company that the minimum closing bid price per share of its American Depositary Shares representing ordinary shares ("ADSs") was below $1.00 for a pe |
Celyad Oncology announces receipt of Nasdaq noticeMONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letter”) on March 31, 2023 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that |
Celyad Oncology SA (NASDAQ:CYAD) Q4 2022 Earnings Call TranscriptCelyad Oncology SA (NASDAQ:CYAD) Q4 2022 Earnings Call Transcript March 24, 2023 Operator: Greetings. Welcome to the Celyad Oncology Full-Year 2022 Financial Results. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. . Please note that this conference is being recorded. At this time, I […] |
Celyad Oncology Appoints Georges Rawadi as Its New CEOMONT-SAINT-GUIBERT, Belgium, March 24, 2023--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased to announce Georges Rawadi as its new Chief Executive Officer (CEO), effective as of March 23, 2023, with starting date April 17, 2023. Michel Lussier will continue to serve as Interim CEO until April 17 to facilitate transition. |
Celyad Oncology reports full year 2022 financial results and recent business highlightsStarting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via (i) strengthening of its research focus centered around NKG2D, B7-H6 and shRNA platforms; (ii) maximizing the value of its IP estate and (iii) driving innovation through strategic collaborations. MONT-SAINT-GUIBERT, Belgium, March 23, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) |
Celyad Oncology to Announce Full Year 2022 Financial Results and Host Conference CallMONT-SAINT-GUIBERT, Belgium, March 17, 2023--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company") (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're beginning the day with a look at the biggest pre-market stock movers traders need to know about for Wednesday morning! |